Cited by 3,212Cytokine Signaling Pathways and InteractionsRheumatoid Arthritis Research and TherapiesPsoriasis: Treatment and Pathogenesis

The pro- and anti-inflammatory properties of the cytokine interleukin-6

Open access
Scheller, Jürgen, Chalaris, Athena, Schmidt-Arras, Dirk, Rose-John, Stefan·2011·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Abstract

Interleukin-6 is a cytokine not only involved in inflammation and infection responses but also in the regulation of metabolic, regenerative, and neural processes. In classic signaling, interleukin-6 stimulates target cells via a membrane bound interleukin-6 receptor, which upon ligand binding associates with the signaling receptor protein gp130. Gp130 dimerizes, leading to the activation of Janus kinases and subsequent phosphorylation of tyrosine residues within the cytoplasmic portion of gp130. This leads to the engagement of phosphatase Src homology domains containing tyrosin phosphatase-2 (SHP-2) and activation of the ras/raf/Mitogen-activated protein (MAP) kinase (MAPK) pathway. In addition, signal transducer and activator of transcription factors are recruited, which are phosphorylated, and consequently dimerize whereupon they translocate into the nucleus and activate target genes. Interestingly, only few cells express membrane bound interleukin-6 receptor whereas all cells display gp130 on the cell surface. While cells, which only express gp130, are not responsive to interleukin-6 alone, they can respond to a complex of interleukin-6 bound to a naturally occurring soluble form of the interleukin-6 receptor. Therefore, the generation of soluble form of the interleukin-6 receptor dramatically enlarges the spectrum of interleukin-6 target cells. This process has been named trans-signaling. Here, we review the involvement of both signaling modes in the biology of interleukin-6. It turns out that regenerative or anti-inflammatory activities of interleukin-6 are mediated by classic signaling whereas pro-inflammatory responses of interleukin-6 are rather mediated by trans-signaling. This is important since therapeutic blockade of interleukin-6 by the neutralizing anti-interleukin-6 receptor monoclonal antibody tocilizumab has recently been approved for the treatment of inflammatory diseases. This article is part of a Special Issue entitled: 11th European Symposium on Calcium.

Integrity signals

Registry

Crossref · 10.1016/j.bbamcr.2011.01.034

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IL-6 trans signaling leads to recruitment of monocytes to the inflammation site, promotes the maintenance of Th17 cells, and inhibits T cell apoptosis and development of Tregs.

    “IL-6 trans signaling also leads to recruitment of monocytes to the inflammation site (42), promotes the maintenance of Th17 cells, and inhibits T cell apoptosis and development of Tregs (43).”
  • IL-6 classic signaling mediates apoptosis inhibition and the regeneration of intestinal epithelial cells.

    “IL-6 classic signaling also mediates apoptosis inhibition and the regeneration of intestinal epithelial cells (43).”
  • C-reactive protein and IL-6 have been linked to immunosenescence in prior studies, but their relationship with systemic chronic inflammation had not been established.

    “Canonical acute inflammation proteins such as C-reactive protein and interleukin (IL)-6 have been associated with immunosenescence in previous studies37,38, but the relationship with systemic chronic inflammation (SCI) has not yet been established.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S.
Affiliations
  • Heinrich Heine University Düsseldorf (DE)
  • Christian-Albrechts-Universität zu Kiel (DE)
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Publisher
Elsevier BV
Published
2011-05
Volume
1813
Issue
5
Pages
878-888
ISSN
0167-4889 (ISSN-L)
OpenAlex
W2110463517
Cited by
3,212
References
14
Citations by year
2026: 134 · 2025: 210 · 2024: 209 · 2023: 198 · 2022: 281 · 2021: 293 · 2020: 301 · 2019: 273 · 2018: 278 · 2017: 313 · 2016: 247 · 2015: 157 · 2014: 124 · 2013: 91 · 2012: 75
FWCI
9.28
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft, Bonn, Germany (SFB415, SFB841, SFB877)
  • Cluster of Excellence “Inflammation at Interfaces.”
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
interleukin-6, gp130, trans-signaling, soluble IL-6 receptor, Janus kinase signaling, SHP2, MAPK signaling, STAT3, inflammation, anti-inflammatory activity, regenerative effect, tocilizumab, cytokine signaling
MeSH terms
Animals, Anti-Inflammatory Agents, Humans, Models, Biological, Signal Transduction, Interleukin-6, Inflammation Mediators, Receptors, Interleukin-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review